Retatrutide: The Triple-G Weight Loss Peptide

TL;DR: Retatrutide (LY3437943), nicknamed "Triple G," is an investigational once-weekly injectable peptide developed by Eli Lilly that simultaneously activates three receptors: GLP-1, GIP, and glucagon. It is the first triple-agonist to reach advanced clinical trials for obesity. In Phase 2 trials published in the New England Journal of Medicine (Jastreboff et al., 2023), the 12mg dose produced 24.2% mean body weight loss at 48 weeks. In Phase 3 TRIUMPH-4 results announced December 2025, participants on 12mg lost an average of 28.7% of body weight at 68 weeks — approximately 71 pounds — the largest weight reduction reported for any anti-obesity medication to date.

What is Retatrutide?

Retatrutide is an investigational single-molecule peptide that activates three incretin and metabolic hormone receptors at once: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. Developed by Eli Lilly under research designation LY3437943, it has earned the nickname "Triple G" for its three-receptor mechanism.

It represents an evolution in the incretin drug class. Semaglutide (Ozempic/Wegovy) targets only GLP-1. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP. Retatrutide adds glucagon receptor activation as a third mechanism — introducing direct effects on energy expenditure and liver fat metabolism that dual-agonist drugs do not provide.

Retatrutide is administered as a once-weekly subcutaneous injection with a half-life of approximately 6 days. As of March 2026, it is not FDA-approved and is in Phase 3 clinical trials (the TRIUMPH program), with a potential FDA submission expected in late 2026.

How It Works

Retatrutide's triple-agonist mechanism engages three distinct pathways, each contributing different metabolic effects:

GLP-1 receptor agonism reduces appetite by acting on hunger centers in the brain, slows gastric emptying to prolong fullness after meals, and stimulates glucose-dependent insulin release. This is the primary pathway behind semaglutide's weight loss effects.

GIP receptor agonism enhances insulin sensitivity, contributes to appetite regulation through brain receptors distinct from GLP-1, and supports a more complete incretin response. GIP and GLP-1 together account for approximately 50-70% of postprandial insulin secretion (Samms et al., 2020).

Glucagon receptor agonism is what sets retatrutide apart from every approved weight loss medication. Glucagon activation:

• Increases energy expenditure — the body burns more calories at rest, addressing a limitation of GLP-1-only drugs which reduce weight primarily through decreased intake (Habegger et al., 2010)
• Promotes liver fat breakdown — glucagon drives hepatic lipid oxidation, directly relevant for fatty liver disease (MASH)
• Stimulates fat mobilization — triggers breakdown of stored fat in adipose tissue

The concern with glucagon is that it raises blood sugar. In retatrutide, this effect is counterbalanced by simultaneous GLP-1 and GIP activation, which enhance insulin secretion. Clinical data confirms retatrutide improves glycemic control despite the glucagon component.

Retatrutide vs Semaglutide

The comparison to semaglutide is the most common question about retatrutide — and the differences are substantial.

The key tradeoff: retatrutide produces nearly double the weight loss of semaglutide, but semaglutide has years of real-world safety data and proven cardiovascular benefits. Tirzepatide sits in between on both efficacy and evidence maturity.

Clinical Trial Results

Phase 2 Trial (Jastreboff et al., 2023)

The landmark Phase 2 trial, published in the New England Journal of Medicine, studied 338 adults with obesity for 48 weeks. Results by dose group:

• Placebo: -2.1% body weight
• 1mg: -8.7%
• 4mg: -17.1%
• 8mg: -22.8%
• 12mg: -24.2%

The 12mg group also saw waist circumference reductions of approximately 20cm (~8 inches) and 72% of prediabetic participants reached normoglycemia. In a MASH sub-study, retatrutide reduced liver fat content by up to 82%, with over 80% of high-dose participants achieving liver fat normalization.

Notably, weight loss curves had not plateaued at 48 weeks for the higher doses — results continued improving.

Phase 3: TRIUMPH-4 (December 2025)

Eli Lilly's first Phase 3 results confirmed and exceeded the Phase 2 data:

• 12mg dose: 28.7% average body weight loss at 68 weeks — approximately 71 pounds from a starting weight of about 248 lbs
• Over half of participants on 12mg lost ≥25% of starting weight
• Knee osteoarthritis pain scores dropped 75.8% in participants with obesity and knee OA
• A 2025 meta-analysis of 878 participants across trials confirmed a mean weight reduction supporting retatrutide's position as the most potent obesity medication in development (PMC12026077)

For perspective: this weight loss approaches what is typically achieved with bariatric surgery, but through a once-weekly injection.

Phase 2 Type 2 Diabetes Trial

A separate trial in adults with type 2 diabetes (Rosenstock et al., 2023) showed HbA1c reductions of up to 2.02 percentage points and weight loss of up to 16.9% at 36 weeks — comparing favorably to tirzepatide in a similar population.

Dosing Protocol

Note: Retatrutide is investigational and not FDA-approved. The following dosing information is from published clinical trial protocols.

Escalation Schedule (12mg target)

All trial protocols used gradual dose escalation to minimize GI side effects:

• Weeks 1-4: 2mg once weekly
• Weeks 5-8: 4mg once weekly
• Weeks 9-12: 8mg once weekly
• Weeks 13+: 12mg once weekly (maintenance)

Lower target doses follow the same escalation pattern, stopping at 4mg or 8mg.

Administration

• Route: Subcutaneous injection, once weekly
• Sites: Abdomen, thigh, or upper arm — rotate sites
• Timing: Same day each week, any time of day, with or without food

Key Principles

• Gradual escalation is essential — skipping steps significantly increases nausea and vomiting
• Dose-dependent results — 12mg produces the most weight loss, but even 4mg achieved 17.1%
• No plateau at 48 weeks — weight loss continued through the full study duration at higher doses

Sourcing quality research peptides matters. For retatrutide, look for suppliers providing third-party HPLC and mass spectrometry testing with every batch. We recommend Fountain of Youth — they carry retatrutide with certificates of analysis and proper cold-chain shipping.

Timeline: What to Expect

Based on Phase 2 trial data (Jastreboff et al., 2023):

Weeks 1-4 (2mg): Appetite reduction is typically the first effect — decreased hunger and earlier satiety. Modest weight loss begins. Some nausea as the body adjusts.

Weeks 5-12 (escalation to 4mg→8mg): Appetite suppression intensifies. Weight loss accelerates noticeably. GI side effects may recur briefly with each dose increase but typically resolve within 1-2 weeks. Many participants had already lost 10-15% of body weight by end of this phase.

Weeks 12-24 (maintenance dose): Rapid weight loss continues. By 24 weeks, the 12mg group had reached approximately 17-19% body weight loss — already exceeding semaglutide's maximum effect. Metabolic markers improve steadily.

Weeks 24-48: Weight loss continues at a gradually decreasing rate. The 12mg group reached 24.2% at 48 weeks. Liver fat reductions become dramatic. GI side effects have typically resolved for most people.

Weeks 48-68: Phase 3 data shows continued loss, reaching 28.7% at 68 weeks. As with all GLP-1 class medications, some weight regain is expected upon discontinuation.

Side Effects & Safety

Gastrointestinal Effects (Most Common)

Like all incretin-based drugs, the most frequently reported side effects are GI-related — nausea, vomiting, diarrhea, and constipation — especially during dose escalation. These are dose-related, mostly mild to moderate, and typically improve over time.

Dysesthesia (Unique to Retatrutide)

Phase 3 trials revealed a side effect not seen with semaglutide or tirzepatide: dysesthesia — abnormal skin sensations like tingling, burning, or heightened sensitivity to touch. This affected 20.9% of participants on 12mg and 8.8% on 9mg, compared to 0.7% on placebo. It was generally mild and rarely caused discontinuation, but it's an important signal to be aware of.

Discontinuation Rates

Treatment discontinuation was higher than in semaglutide trials. In TRIUMPH-4, discontinuation rates were 12.2% at 9mg and 18.2% at 12mg vs 4% for placebo. Notably, some participants discontinued because they felt they were losing weight too quickly — not because of intolerable side effects.

Other Safety Considerations

• Heart rate: Small increases (2-4 bpm) consistent with other GLP-1 drugs
• Gallbladder risk: Rapid weight loss from any cause increases gallstone risk — not unique to retatrutide but worth monitoring
• Pancreatitis: Being monitored; no clear signal in trials so far, but a class-wide concern for GLP-1 drugs
• Lean mass: Like all large-weight-loss interventions, some lean mass is lost alongside fat. The glucagon component's effect on body composition is being evaluated in Phase 3. Resistance training and adequate protein are recommended
• Thyroid: GLP-1 agonists carry a boxed warning for medullary thyroid carcinoma (MTC) risk based on rodent studies. Contraindicated in individuals with personal/family history of MTC or MEN 2
• Pregnancy: Should not be used during pregnancy; discontinue at least 2 months before planned pregnancy due to long half-life

Weight Loss Peptides Compared (2026)

Retatrutide currently produces the most weight loss of any medication ever studied, approaching results previously achievable only through bariatric surgery — but through a once-weekly injection.

Where to Buy Retatrutide

Retatrutide is not FDA-approved and is not available by prescription. It is available as a research peptide from select suppliers.

When sourcing retatrutide, quality is critical — the FDA has warned about unapproved retatrutide products being marketed without proper manufacturing standards. Look for suppliers with:

• Third-party HPLC and mass spectrometry testing
• Published certificates of analysis for every batch
• Proper cold-chain shipping (peptides degrade without refrigeration)

We recommend Fountain of Youth for third-party tested retatrutide with full COA documentation.

Frequently Asked Questions

What is retatrutide? Retatrutide (LY3437943), nicknamed "Triple G," is an investigational once-weekly injectable peptide developed by Eli Lilly. It is the first triple-receptor agonist, simultaneously activating GLP-1, GIP, and glucagon receptors. In Phase 3 trials, the 12mg dose produced 28.7% average body weight loss — the largest reduction ever recorded for an anti-obesity medication.

How is retatrutide different from semaglutide? Semaglutide (Wegovy/Ozempic) targets one receptor (GLP-1) and produces about 15% weight loss. Tirzepatide (Zepbound) targets two (GLP-1 + GIP) for about 22.5%. Retatrutide targets all three (GLP-1 + GIP + glucagon), achieving up to 28.7% — nearly double semaglutide. The glucagon component uniquely increases energy expenditure and promotes liver fat reduction.

How much weight can you lose on retatrutide? In Phase 3 TRIUMPH-4 trials, participants on 12mg lost an average of 28.7% of body weight at 68 weeks — roughly 71 pounds from a starting weight of about 248 pounds. Over half of participants on the highest dose lost at least 25% of their starting weight. Individual results vary based on dose, diet, activity, and baseline weight.

What are the side effects of retatrutide? Common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — especially during dose escalation. A side effect unique to retatrutide is dysesthesia (tingling or unusual skin sensations), affecting about 20.9% at the 12mg dose. Discontinuation rates were 12-18% at higher doses. Gradual dose titration minimizes GI issues.

Is retatrutide FDA approved? No. As of March 2026, retatrutide is not FDA approved and remains investigational. Phase 3 TRIUMPH trials are expected to complete in 2026, with Eli Lilly anticipated to file for approval in late 2026 and a possible FDA decision in 2027. It is currently available as a research peptide.

Retatrutide vs semaglutide — which produces more weight loss? Retatrutide produces significantly more weight loss. Semaglutide's STEP 1 trial showed 14.9% at 68 weeks, while retatrutide's TRIUMPH-4 showed 28.7% at 68 weeks — nearly double. However, semaglutide is FDA-approved with extensive long-term safety data, while retatrutide is still investigational.

What is the best peptide for weight loss in 2026? Among FDA-approved options, tirzepatide (Zepbound) leads with about 22.5% weight loss. Semaglutide (Wegovy) is the most established at about 15%. Retatrutide is the most potent in trials at 28.7% but is not yet approved. For research purposes, retatrutide and other incretin-based peptides are available from third-party tested suppliers.

What dose of retatrutide works best for weight loss? In clinical trials, 12mg once weekly produced the greatest weight loss (28.7% at 68 weeks), but all doses showed meaningful results — even 4mg produced 17.1% loss. All protocols use gradual escalation: 2mg for 4 weeks, then 4mg, then 8mg, then 12mg, increasing every 4 weeks to minimize side effects.

Sources

1. Jastreboff, A.M., Kaplan, L.M., Frias, J.P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. The New England Journal of Medicine, 389(6), 514-526. DOI: 10.1056/NEJMoa2301972

2. Rosenstock, J., Frias, J.P., Jastreboff, A.M., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet, 402(10401), 529-544. DOI: 10.1016/S0140-6736(23)01053-X

3. Eli Lilly (2025). TRIUMPH-4 Phase 3 results: Retatrutide in obesity with knee osteoarthritis. Lilly Investor Relations

4. Coskun, T., Urva, S., Roell, W.C., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 34(9), 1234-1247. DOI: 10.1016/j.cmet.2022.07.013

5. Habegger, K.M., Heppner, K.M., Geary, N., et al. (2010). The metabolic actions of glucagon revisited. Nature Reviews Endocrinology, 6(12), 689-697. DOI: 10.1038/nrendo.2010.187

6. Samms, R.J., Coghlan, M.P., & Sloop, K.W. (2020). How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism, 31(6), 410-421. DOI: 10.1016/j.tem.2020.02.006

7. Systematic review and meta-analysis: Retatrutide as a potential game changer in obesity pharmacotherapy. PMC, 2025. PMC12190491

8. Meta-analysis of 878 participants across retatrutide clinical trials. PMC, 2025. PMC12026077